ESR2 and neoplasm: It has also been shown that the use of an epigenetic modulator of ERβ expression, a histone deacetylase inhibitor, induces an increase in the expression of the ERβ1 isoform, which acts as a tumor suppressor, but not the ERβ5 isoform, which drives the oncogenic function [67].